Sometimes it is the simple, very reasonable questions that patients ask that stop us and make us think. Often the question is simpler than the answer. “Should members of my family be checked to see if they have the same thyroid problem?” The simple answer is “Probably.” The more detailed answer is given below.
Certainly, autoimmune conditions tend to run in families. So, if a patient has either Hashimoto’s thyroiditis or Graves’ disease, there is a 7–10x increased chance of other family members developing that condition. Complex polygenic factors are involved, including HLA-DR genes, and in the case of Graves’ disease, TSHR genes are also involved. This is why the American Thyroid Association (ATA) recommends that individuals with a family history of thyroid disease should have their thyroid function tested starting at age 35 and every five years thereafter.
In the case of thyroid nodules and goitres, there is a 3–5x increased risk of developing a thyroid nodule or a goitre in first degree relatives of a family member with a thyroid nodule or a goitre. The most common type of thyroid cancer is papillary thyroid carcinoma (PTC). Most cases of PTC are sporadic but about 5–10% are thought to be familial. Familial PTC is often multifocal, may affect younger individuals, and some studies suggest that it is more aggressive than non-familial PTC. Familial PTC is autosomal dominant. No specific genetic mutation has been detected.
Certain genetic syndromes, including familial adenomatous polyposis, PTEN-hamartoma syndrome, Carney complex and Cowden’s disease are all associated with an increased risk of developing thyroid carcinoma.
Medullary thyroid carcinoma (MTC) is much less common that papillary thyroid carcinoma. About 80% of cases of MTC are sporadic with the remaining 20% of cases familial. There is a lot written about familial MTC and the genetics are well known. The gene involved is the RET proto-oncogene and the mode of inheritance is autosomal dominant. Familial MTC is part of the multiple endocrine neoplasia syndrome (MEN). There are two main types of MEN that are associated with MTC:
- MEN2a: the more common type.
- MEN2b: the less common type. Marfanoid features and mucosal neuromas.
In addition to this, there is also familial MTC that does not have the other features of MEN2a but is probably best classified as a variant of MEN2a.
The ATA recommends genetic testing of all patients with MTC. Family members of patients with MTC and the RET proto-oncogene can be screened to see if they are a carrier of the RET proto-oncogene and therefore at risk of developing MTC. Genetic mutations of the RET proto-oncogene are classified as highest risk (HST), high risk (H) or moderate risk (MOD). Family members with RET proto-oncogene are offered prophylactic total thyroidectomy. This is similar to the concept of prophylactic mastectomy in women with the BRCA1 or BRCA2 gene mutation.
Those with the highest risk mutation (RET codon M918T) are offered prophylactic thyroidectomy before the age of one.
Women are 5–8x more likely to develop thyroid disorders than men. While genetics loads the gun, environmental factors may pull the trigger for thyroid disorders. Common environmental factors that interact with genetic predisposition include: iodine intake (either too much or too little), selenium, vitamin A, chemicals (bisphenol, phthalates), radiation and stress (which can trigger an autoimmune response). Because individuals in the same household are usually exposed to similar environmental factors, it is often difficult to determine whether a thyroid disorder is due to genetic factors, environmental factors or both.
Summary
Family members of patients with medullary thyroid carcinoma and RET proto-oncogene should be screened for this gene and appropriate treatment should be instigated as per the ATA guidelines. Family members with a family history of familial papillary thyroid carcinoma should have a thyroid ultrasound and FNA of any suspicious thyroid nodules. There is no consensus as to when screening for familial PTC should begin, but as familial PTC tends to occur at a younger age than the more common non-familial PTC, it seems reasonable to do an ultrasound scan of the thyroid at the age of 18. Family members of patients with Hashimoto’s thyroiditis or Graves’ disease should have thyroid function tests, TPO antibodies and TSHR antibodies checked every five years from the age of 35 as per the ATA guidelines.
References:
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012 Dec;22(12):1200–35.
- Oakley GM, Curtin K, Pimentel R, et al. Establishing a familial basis for papillary thyroid carcinoma using the Utah Population Database. JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1171–4.
- Maxwell EL, Hall FT, Freeman JL. Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope 2004 Dec;114(12):2182–6.
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25(6): 567–610.